title: The impact of osteoporosis in men treated for prostate cancer.
abstract: Prostate cancer patients are at significant risk for SREs, with up to 50% of androgen-insensitive patients experiencing an SRE at 24 months. The risk increases with the duration and type of cancer treatment. SREs decrease HRQOL, increase the cost of care, and are associated negatively with overall survival. Screening men at greatest risk (slender white men and men with hormone refractory disease or metastatic disease) with BMD measurements, and initiating empiric therapy (vitamin D3, calcium, parenteral estrogens, bisphosphates) may be warranted.
authors.affiliation: Department of Urology, Case Western Reserve University School of Medicine, University Hospitals of Cleveland, 11100 Euclid Avenue, Cleveland, OH 44106, USA. michael.oefelein@uhhs.com
authors.forename: Michael G
authors.initials: MG
authors.lastname: Oefelein
authors.forename: Martin I
authors.initials: MI
authors.lastname: Resnick
mesh_terms: D000368:Aged; D000726:Androgen Antagonists / Q000009:adverse effects* / Q000627:therapeutic use; D018931:Antineoplastic Agents, Hormonal / Q000009:adverse effects* / Q000627:therapeutic use; D015519:Bone Density / Q000502:physiology; D003720:Densitometry; D004305:Dose-Response Relationship, Drug; D005500:Follow-Up Studies; D005598:Fractures, Spontaneous / Q000453:epidemiology / Q000209:etiology*; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009919:Orchiectomy / Q000009:adverse effects; D010024:Osteoporosis / Q000175:diagnosis / Q000453:epidemiology* / Q000209:etiology*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000628:therapy*; D018570:Risk Assessment
chemical_list: D000726:Androgen Antagonists; D018931:Antineoplastic Agents, Hormonal